BR112022011072A2 - Intensificação de célula imune efetora derivada de ipsc usando compostos pequenos - Google Patents
Intensificação de célula imune efetora derivada de ipsc usando compostos pequenosInfo
- Publication number
- BR112022011072A2 BR112022011072A2 BR112022011072A BR112022011072A BR112022011072A2 BR 112022011072 A2 BR112022011072 A2 BR 112022011072A2 BR 112022011072 A BR112022011072 A BR 112022011072A BR 112022011072 A BR112022011072 A BR 112022011072A BR 112022011072 A2 BR112022011072 A2 BR 112022011072A2
- Authority
- BR
- Brazil
- Prior art keywords
- derived
- ipsc
- immune effector
- effector cell
- enhanced
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000012642 immune effector Substances 0.000 title abstract 2
- 229940121354 immunomodulator Drugs 0.000 title abstract 2
- 239000012636 effector Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 238000010362 genome editing Methods 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4637—Other peptides or polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
- C12N2500/62—DMSO
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
INTENSIFICAÇÃO DE CÉLULA IMUNE EFETORA DERIVADA DE IPSC USANDO COMPOSTOS PEQUENOS. Trata-se de métodos e composições para obtenção de células efetoras derivadas funcionalmente intensificadas, obtidas a partir da diferenciação direcionada de iPSCs manipuladas genomicamente. As células derivadas fornecidas no presente documento têm edição estável e funcional do genoma que entrega efeitos terapêuticos melhorados ou intensificados. Também são fornecidas composições terapêuticas e uso das mesmas compreendendo as células efetoras derivadas funcionalmente intensificadas sozinhas, ou com anticorpos ou inibidores de ponto de verificação em terapias combinadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962945040P | 2019-12-06 | 2019-12-06 | |
PCT/US2020/063457 WO2021113744A1 (en) | 2019-12-06 | 2020-12-04 | Enhancement of ipsc-derived effector immune cell using small compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022011072A2 true BR112022011072A2 (pt) | 2022-08-23 |
Family
ID=76221001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022011072A BR112022011072A2 (pt) | 2019-12-06 | 2020-12-04 | Intensificação de célula imune efetora derivada de ipsc usando compostos pequenos |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230016034A1 (pt) |
EP (1) | EP4069827A4 (pt) |
JP (1) | JP2023505206A (pt) |
KR (1) | KR20220124179A (pt) |
CN (1) | CN115087731A (pt) |
AU (1) | AU2020395239A1 (pt) |
BR (1) | BR112022011072A2 (pt) |
CA (1) | CA3160423A1 (pt) |
IL (1) | IL293564A (pt) |
MX (1) | MX2022006725A (pt) |
WO (1) | WO2021113744A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220387488A1 (en) * | 2021-05-12 | 2022-12-08 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies |
WO2022269393A1 (en) * | 2021-06-23 | 2022-12-29 | Crispr Therapeutics Ag | Engineered cells with improved protection from natural killer cell killing |
IL309797A (en) * | 2021-07-02 | 2024-02-01 | Fate Therapeutics Inc | Protected effector cells and their use in allogeneic cellular therapies |
WO2023081901A1 (en) * | 2021-11-08 | 2023-05-11 | Fate Therapeutics, Inc. | Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors |
TW202340453A (zh) * | 2022-01-28 | 2023-10-16 | 中國大陸商杭州啟函生物科技有限公司 | 用於基於細胞的免疫療法的方法和組合物 |
WO2023196994A1 (en) * | 2022-04-08 | 2023-10-12 | Fate Therapeutics, Inc. | Cells having solid tumor targeting backbone and use thereof |
WO2024097911A1 (en) * | 2022-11-02 | 2024-05-10 | Fate Therapeutics, Inc. | Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting gprc5d |
CN117305241B (zh) * | 2023-11-28 | 2024-03-19 | 上海兴瑞一达生物科技有限公司 | 一种hiPSCs诱导分化为NK细胞的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2992551A1 (en) * | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
WO2017127755A1 (en) * | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
KR102175256B1 (ko) * | 2016-02-01 | 2020-11-06 | 주식회사 녹십자랩셀 | 세포의 동결보존용 배지 조성물 및 이의 용도 |
PT3618842T (pt) * | 2017-05-01 | 2024-01-12 | Juno Therapeutics Inc | Combinação de uma terapia celular e de um composto imunomodulador |
JP2020528885A (ja) * | 2017-07-19 | 2020-10-01 | フェイト セラピューティクス,インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
AU2018381191A1 (en) * | 2017-12-08 | 2020-06-04 | Fate Therapeutics, Inc. | Immunotherapies using enhanced iPSC derived effector cells |
SG11202100260QA (en) * | 2018-07-13 | 2021-02-25 | Univ Kyoto | METHOD FOR PRODUCING γδ T CELLS |
-
2020
- 2020-12-04 CN CN202080095636.2A patent/CN115087731A/zh active Pending
- 2020-12-04 KR KR1020227023102A patent/KR20220124179A/ko unknown
- 2020-12-04 BR BR112022011072A patent/BR112022011072A2/pt unknown
- 2020-12-04 WO PCT/US2020/063457 patent/WO2021113744A1/en unknown
- 2020-12-04 JP JP2022533373A patent/JP2023505206A/ja active Pending
- 2020-12-04 EP EP20896968.3A patent/EP4069827A4/en active Pending
- 2020-12-04 AU AU2020395239A patent/AU2020395239A1/en active Pending
- 2020-12-04 IL IL293564A patent/IL293564A/en unknown
- 2020-12-04 MX MX2022006725A patent/MX2022006725A/es unknown
- 2020-12-04 US US17/782,600 patent/US20230016034A1/en active Pending
- 2020-12-04 CA CA3160423A patent/CA3160423A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115087731A (zh) | 2022-09-20 |
CA3160423A1 (en) | 2021-06-10 |
IL293564A (en) | 2022-08-01 |
US20230016034A1 (en) | 2023-01-19 |
MX2022006725A (es) | 2022-08-22 |
JP2023505206A (ja) | 2023-02-08 |
EP4069827A1 (en) | 2022-10-12 |
WO2021113744A1 (en) | 2021-06-10 |
AU2020395239A1 (en) | 2022-06-23 |
EP4069827A4 (en) | 2024-05-29 |
KR20220124179A (ko) | 2022-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022011072A2 (pt) | Intensificação de célula imune efetora derivada de ipsc usando compostos pequenos | |
BR112022005602A2 (pt) | Células efetoras de múltiplos direcionamentos e uso das mesmas | |
BR112022000641A2 (pt) | Modificação genética de célula efetora imune e uso da mesma | |
BR112021019772A2 (pt) | Reconstituição de cd3 em células efetoras imunes e ipsc geneticamente modificadas | |
MX2020009896A (es) | Celulas efectoras inmunitarias modificadas y usos de las mismas. | |
MX2020005477A (es) | Inmunoterapias con el uso de células efectoras potenciadas derivadas de ipsc. | |
MX2020005701A (es) | Células efectoras inmunitarias potenciadas y usos de las mismas. | |
BR112022006440A2 (pt) | Receptor de antígeno quimérico intensificado para manipulação de célula efetora imune e uso do mesmo | |
MX2021006194A (es) | Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc. | |
BR112022025806A2 (pt) | Combinação de tipos de células efetoras derivadas de ipsc para uso em imunoterapia | |
BR112016013400A2 (pt) | métodos para modificar um genoma e para produzir um camundongo | |
BR112018076190A2 (pt) | ortólogos e sistemas crispr tipo vi | |
BR112017019140A2 (pt) | métodos de tratamento de câncer usando células t ativadas | |
MX2018001617A (es) | Composiciones de crispr-cas9 diseñados y metodos de uso. | |
MX2022006948A (es) | Composiciones y metodos para programar celulas terapeuticas utilizando nanoportadores de acidos nucleicos dirigidos. | |
BR112018003535A2 (pt) | receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão | |
NZ730563A (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
MX2019013690A (es) | Conjugados de farmaco-proteina con ciclodextrina. | |
MX362442B (es) | Inhibidores de enzima 1 dependiente de inositol (ire-1alfa). | |
BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
EP3943092A3 (en) | Compositions for use in inducing differentiation of human brown adipocyte progenitors | |
MX2023004326A (es) | Células madre pluripotentes inducidas (ipsc) multiplexadas modificadas y células efectoras inmunitarias dirigidas a tumores sólidos. | |
MX2023005029A (es) | Celula pluripotente inducida (ipsc) modificada geneticamente y celulas efectoras inmunitarias persistentes. | |
BR112021026002A2 (pt) | Regeneração e transformação melhorada de plantas com a ajuda de um gene de reforço grf1 | |
MX2018010196A (es) | Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas. |